A Study of BL-B01D1 + SI-B003 in Patients With Unresectable, Locally Advanced or Recurrent Metastatic...
Locally Advanced or Recurrent Metastatic HER-2 Negative Breast CancerPrimary objective: To explore the efficacy of BL-B01D1+SI-B003 combination therapy in inoperable locally advanced or recurrent metastatic HER-2 patients Efficacy, safety, and tolerability in patients with negative breast cancer, and the optimal dose and administration mode of the combination are further explored. Secondary objective: To explore PK, immunogenicity and drug-drug interaction (DDI) of BL-B01D1 and SI-B003.
"neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative...
Triple Negative Breast NeoplasmsNeoadjuvant treatment is an important part of the treatment strategy for locally advanced TNBC having established a positive and significant correlation of pathologic Complete Response (pCR) with long-term clinical benefit such as Event-Free Survival (EFS) and Overall Survival (OS) as shown via large meta-analysis. Much effort has been made to identify novel agents and new drug combinations that can improve pCR rates in this specific clinical setting, which is the leading rationale to evaluate RP1 oncolytic immunotherapy in combination with Atezolizumab.
Digital Tool Enhancing GPs' Information Management for Patients With Multimorbidity - a Pilot Study...
AsthmaBreast Neoplasms8 moreThe gp-multitool.de study is a cluster-randomized controlled trial that aims to enhance evidence-based and patient-centered care for patients with multimorbidity by assessing and providing information relevant for the primary care of this patient group. This pilot study examines the feasibility of the gp-multitool.de study, i.e., intervention and evaluation in GP practices in urban and rural administrative districts in Germany.
SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer...
Breast CancerProspective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients. Bi-centric with ETHOS center : ICM (Institut du Cancer de Montpellier) and ISC (Institut Sainte Catherine) Avignon 500 patients will be included: COHORTE A = Treatment ETHOS RT :46 evaluable patients with high risk of LRR and bf+ risk COHORT B = Conventional IMRT : 454 others patients with high risk of LRR and bf- risk
Surgical or Medical Treatment of Breast Cancer Metastasis: A Multicentre Observational Study
Breast CancerLiver MetastasesThe liver represents the third most common site of breast cancer (BC) metastases behind the lymphatics and bone. The primary treatment for BCLM remains chemo-therapy and, more recently, targeted immunotherapy. The role of liver resection in BCLM remains controversial. The primary aim of the study is to compare the efficacy of liver resection vs. medical therapy alone in Breast Cancer Liver Metastasis (BCLM) patients.
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative...
Metastatic Triple-Negative Breast CancerThe goal of this phase II study is to test the combination of trilaciclib, pembrolizumab, gemcitabine, and carboplatin in locally advanced unresectable or metastatic triple-negative breast cancer. The main questions it aims to answer are: to evaluate the anti-cancer efficacy (assess how well it works) to evaluate the safety and tolerability (how well the body can handle the treatment) of this combination of anti-cancer therapy
Pre-operative Therapy in Breast Cancer
Breast CancerThis is a prospective and retrospective study to evaluate the effect of pre-operative therapy on response and survival, and compare the difference in response and survival by pre-operative regimen or by patient's clinicopathological characteristic in early or advanced breast cancer.
Feasibility of Implementing Acupuncture Into Federally Qualified Health Center Among Breast Cancer...
Breast CancerThe purpose of this study is to test the feasibility of implementing acupuncture intervention in federally qualified health centers oncology clinics for breast cancer survivors.
Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential...
CarcinomaNon-Small-Cell Lung1 moreThis is an open-label, single-arm, Phase II investigator-initiated trial of vinorelbine metronomic chemotherapy combined with hypofractionated radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for treatment of advanced refractory non-small cell lung cancer and breast cancer.
Evaluate Efficacy and Safety of LACUDY for Improving Vaginal Environment in Breast Cancer Patient...
Hormone Receptor-positive Breast CancerAdjuvant hormone treatments for early breast cancer are associated with frequent bothersome side effects with major negative impact on patients' quality of life and treatment adherence. Patients most commonly report menopausal symptoms including vaginal dryness, vaginal bleeding, and dyspareunia. Even though previous studies have reported that estrogen topical agent relives these symptoms, non-hormonal therapy should be considered first due to concerns about the role of estrogen in breast cancer development. Therefore, this trial is planned to evaluate the efficacy and safety of LacuD (hyaluronic acid, lactic acid and alginate) in the vaginal environment of breast cancer patients receiving hormone therapy.